Last reviewed · How we verify

NCT06366425: HEPGEN

Screening for Chronic Liver Diseases in General Population

Recruiting now NA Last updated 10 July 2025
What this trial tests

NA trial testing Blood sample then fibroscan in Fibrosis, Liver in 260 participants. Currently enrolling.

Timeline
11 September 2024
Primary endpoint
9 October 2024
1 January 2029

Quick facts

Lead sponsorUniversity Hospital, Montpellier
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment260
Start date11 September 2024
Primary completion9 October 2024
Estimated completion1 January 2029
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

40 and older, any sex, with Fibrosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fibrosis, Liver

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06366425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing